Clinical Trials Browser

Phase 2 × Cholangiocarcinoma × Neoadjuvant Therapy × Clear all

NCT04523402 2020-08-21

Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Phase 2 Unknown

Gastrointestinal

Cholangiocarcinoma

NCT04506281 2020-08-10

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Phase 2 Unknown

Gastrointestinal

Cholangiocarcinoma